SSRIs: Bad to the Bone?

Based on SSRIs: Bad to the Bone? (Sansone and Sansone, 2012)

Abstract

Selective serotonin reuptake inhibitors are globally popular antidepressants with broad clinical indications. Despite an overall favorable side-effect profile, our examination of 19 studies, one review, and one meta-analysis indicates that these unique antidepressants appear to have negative effects on bone, particularly with regard to bone mineral density and fracture risk. These risks may be enhanced by more serotonergic agents and/or longer exposure to selective serotonin reuptake inhibitors. The magnitude of this relationship is difficult to determine due to the myriad of potential confounds in available studies, but all indicate risk. In additional support of these findings, serotonin receptors have been identified on osteoclasts, osteoblasts, and osteocyte cell lines, suggesting that serotonin may be an important regulatory agent in bone. While no formal recommendations regarding the use of selective serotonin reuptake inhibitors in risk populations are available, caution is advised in individuals with potential risk (i.e., those with osteoporosis or histories of osteoporotic fractures).

Keywords: Bone, fractures, osteoporosis, selective serotonin reuptake inhibitors, SSRIs, skeleton

Sansone, R.A.,and Sansone, L.A. (2012). SSRIs: Bad to the Bone? Innov Clin Neurosci9, 42–47.